XML 60 R36.htm IDEA: XBRL DOCUMENT v3.25.2
Research Collaboration and License Agreements - Additional Information (Details) - USD ($)
 1 Months Ended 3 Months Ended 4 Months Ended 6 Months Ended 12 Months Ended 14 Months Ended 47 Months Ended 62 Months Ended
Nov. 30, 2017
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2015
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2018
Jun. 30, 2025
Jun. 30, 2025
Aug. 12, 2024
Dec. 31, 2024
May 31, 2024
Apr. 30, 2024
Dec. 31, 2023
Jul. 31, 2021
Jun. 30, 2019
Dec. 31, 2017
Research Collaboration And License Agreements [Line Items]                                  
Contract revenue receivable if milestones achieved   $ 4,100,000 $ 10,700,000   $ 4,100,000 $ 10,700,000   $ 4,100,000 $ 4,100,000   $ 7,800,000     $ 9,400,000      
Collaboration contract asset and other assets   4,400,000     4,400,000     4,400,000 4,400,000   8,100,000            
Contract with customer, liability   237,000,000.0 599,200,000   237,000,000.0 599,200,000   237,000,000.0 237,000,000.0   $ 448,200,000     549,200,000      
Revenue, remaining performance obligation   237,000,000.0     237,000,000.0     237,000,000.0 237,000,000.0                
Revenue   22,400,000 76,500,000   211,200,000 101,800,000                      
Operating expenses   (93,900,000) (125,000,000.0)   (211,300,000) (233,600,000)                      
Net loss   $ (61,200,000) $ (35,200,000)   $ 21,700,000 $ (104,600,000)                      
Basic (in dollars per share)   $ (0.84) $ (0.49)   $ 0.30 $ (1.46)                      
Diluted (in dollars per share)   $ (0.84) $ (0.49)   $ 0.30 $ (1.46)                      
Removal of Combination Trials                                  
Research Collaboration And License Agreements [Line Items]                                  
Revenue         $ 150,200,000                        
Operating expenses         (2,600,000)                        
Net loss         $ 147,600,000                        
Basic (in dollars per share)         $ 2.04                        
Diluted (in dollars per share)         $ 2.03                        
Updated Research Timelines                                  
Research Collaboration And License Agreements [Line Items]                                  
Revenue         $ (2,500,000)                        
Net loss         $ (2,500,000)                        
Basic (in dollars per share)         $ (0.03)                        
Diluted (in dollars per share)         $ (0.03)                        
Pfizer, Inc.                                  
Research Collaboration And License Agreements [Line Items]                                  
Payments received             $ 28,000,000.0                    
Pfizer, Inc. | Collaboration Agreement                                  
Research Collaboration And License Agreements [Line Items]                                  
Contract revenue receivable if milestones achieved                             $ 650,000,000.0    
Collaboration agreement direct and incremental costs incurred         $ 12,900,000                        
Collaboration contract asset and other assets   $ 12,900,000     12,900,000     12,900,000 12,900,000                
Pfizer, Inc. | Regulatory and Sales-Based Milestones | Maximum                                  
Research Collaboration And License Agreements [Line Items]                                  
Contract revenue receivable if milestones achieved                             1,400,000,000    
Pfizer, Inc. | Regulatory Milestone Related to Marketing Approvals                                  
Research Collaboration And License Agreements [Line Items]                                  
Contract revenue receivable if milestones achieved                             400,000,000.0    
Payments received                 0                
Pfizer, Inc. | Sales-Based Milestones                                  
Research Collaboration And License Agreements [Line Items]                                  
Contract revenue receivable if milestones achieved                             $ 1,000,000,000.0    
Pfizer, Inc. | Option Payments To License Agreement | Maximum                                  
Research Collaboration And License Agreements [Line Items]                                  
Contract revenue receivable if milestones achieved   3,800,000     3,800,000     3,800,000 3,800,000                
Pfizer, Inc. | Development Milestone Payments | Maximum                                  
Research Collaboration And License Agreements [Line Items]                                  
Contract revenue receivable if milestones achieved                                 $ 225,000,000
Pfizer, Inc. | Sales Based Milestone Payments                                  
Research Collaboration And License Agreements [Line Items]                                  
Payments received         0       0                
Pfizer, Inc. | Sales Based Milestone Payments | Maximum                                  
Research Collaboration And License Agreements [Line Items]                                  
Contract revenue receivable if milestones achieved                                 $ 550,000,000
Novartis Pharma AG | License                                  
Research Collaboration And License Agreements [Line Items]                                  
Payments received               0                  
Contract with customer, liability                       $ 150,000,000          
Contingent payments                       $ 1,010,000,000.00          
Revenue recognized         20,000,000                        
Revenue, remaining performance obligation   130,000,000     130,000,000     130,000,000 130,000,000                
Capitalized costs                         $ 3,000,000        
Bayer Collaboration Agreement                                  
Research Collaboration And License Agreements [Line Items]                                  
Contract revenue receivable if milestones achieved                               $ 17,500,000  
Bayer Collaboration Agreement | Development Milestone Payments                                  
Research Collaboration And License Agreements [Line Items]                                  
Payments received                   $ 0              
Bayer Collaboration Agreement | Development Milestone Payments | Maximum                                  
Research Collaboration And License Agreements [Line Items]                                  
Contract revenue receivable if milestones achieved                               197,500,000  
Bayer Collaboration Agreement | Sales Based Milestone Payments                                  
Research Collaboration And License Agreements [Line Items]                                  
Payments received                   $ 0              
Bayer Collaboration Agreement | Sales Based Milestone Payments | Maximum                                  
Research Collaboration And License Agreements [Line Items]                                  
Contract revenue receivable if milestones achieved                               $ 490,000,000  
Bayer Collaboration Agreement | Research Funding Payments                                  
Research Collaboration And License Agreements [Line Items]                                  
Contract revenue receivable if milestones achieved                           $ 12,000,000.0      
Genentech                                  
Research Collaboration And License Agreements [Line Items]                                  
Payments received $ 34,500,000     $ 11,000,000.0 0                        
Genentech | Regulatory Milestone Related to Marketing Approvals                                  
Research Collaboration And License Agreements [Line Items]                                  
Contract revenue receivable if milestones achieved   52,500,000     52,500,000     52,500,000 52,500,000                
Genentech | Development Milestone Payments | Maximum                                  
Research Collaboration And License Agreements [Line Items]                                  
Contract revenue receivable if milestones achieved   44,000,000     44,000,000     44,000,000 44,000,000                
Genentech | Commercial Milestones                                  
Research Collaboration And License Agreements [Line Items]                                  
Contract revenue receivable if milestones achieved   $ 60,000,000     $ 60,000,000     $ 60,000,000 $ 60,000,000